Literature DB >> 4082106

Anticoagulant and lipolytic effects of a low molecular weight heparin fraction.

J Harenberg, A Gnasso, J X de Vries, R Zimmermann, J Augustin.   

Abstract

The lipolytic and anticoagulant actions of a 4000 dalton low molecular weight (LMW) heparin were compared with unfractionated mucosal heparin after intravenous and various subcutaneous doses in man. I.v. injection of 100 USP units/kg body weight lipoprotein lipase (LPL) activity, and inhibition of factor Xa decreased with a half life twice as long after LMW heparin compared to normal heparin (p less than 0.05). There were no differences in half lives for HTGL activity, thrombin inhibition and on aPTT. The area under the activity time curve (AUC) of LPL and factor Xa was double with LMW heparin (p less than 0.05). S.c. administration showed that the AUC of LMW heparin on the factor Xa inhibition was 10 times larger compared to normal heparin. LPL activity was released comparable to normal heparin. The effects on HTGL were three times larger compared to normal heparin. There were no differences in half lives. The data show that in contrast to normal heparin LMW heparin is rapidly and completely absorbed from the subcutaneous depots. The pharmacodynamic data of LPL activity and factor Xa inhibition suggest similar release mechanisms.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4082106     DOI: 10.1016/0049-3848(85)90252-x

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Effect of anticoagulants in vitro on the viability of lymphocytes and content of free fatty acids in plasma.

Authors:  A Klein; S Ramcharitar; N Christeff; E Nisbett-Brown; E Nunez; A Malkin
Journal:  In Vitro Cell Dev Biol       Date:  1991-04

2.  [Neutralization of low molecular weight heparin Kabi 2165 by protamine chloride].

Authors:  J Harenberg; C Giese; A Knödler; R Zimmermann; G Schettler
Journal:  Klin Wochenschr       Date:  1986-11-17

3.  [Ambulatory long-term prevention of thromboembolism with low-molecular weight heparin].

Authors:  J Harenberg; G Leber; J Augustin; R Raedsch; F Schwarz; A Stiehl; R Zimmermann
Journal:  Klin Wochenschr       Date:  1987-04-01

Review 4.  Anticoagulant effects of idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials.

Authors:  Job Harenberg; Ingrid Jörg; Yvonne Vukojevic; Gerd Mikus; Christel Weiss
Journal:  Eur J Clin Pharmacol       Date:  2008-06       Impact factor: 2.953

5.  Low-Mr heparin is as potent as conventional heparin in releasing lipoprotein lipase, but is less effective in preventing hepatic clearance of the enzyme.

Authors:  G Q Liu; G Bengtsson-Olivecrona; P Ostergaard; T Olivecrona
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.